Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 3704502
Author(s) Marzolini, Catia; Buclin, Thierry; Decosterd, Laurent Arthur; Biollaz, Jérôme; Telenti, Amalio
Author(s) at UniBasel Marzolini, Catia
Year 2001
Title Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability
Journal Therapeutic drug monitoring
Volume 23
Number 4
Pages / Article-Number 394-8
Mesh terms Adult; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections, metabolism; HIV Protease Inhibitors, pharmacokinetics; Humans; Male; Nelfinavir, pharmacokinetics
Abstract Nelfinavir has been recently approved as a twice-daily (BID) dose regimen, but no evaluation of the influence of this regimen change on patients' protease inhibitor exposure has been published. The aim of this study was to compare trough plasma concentrations of nelfinavir obtained under the 1250-mg b.i.d regimen with the levels achieved with the original 750-mg three-times-daily (TID) regimen in 56 HIV-infected patients. Blood samples were obtained at steady state before the morning dose of nelfinavir. Plasma levels were measured by high-performance liquid chromatography. Eleven and 45 patients were following TID and BID regimens, respectively. Trough concentrations ranged from 0.14 to 11.74 mg/L and from 0.36 to 10.57 mg/L under TID and BID regimens, respectively. Large interpatient (coefficient of variation: 153%) and modest intrapatient (45%) variabilities of nelfinavir levels were observed. Twenty-one patients (38%) and six patients (11%) had levels above and below, respectively, the trough nelfinavir range (1.0--3.0 mg/L) recommended by the manufacturer. Trough levels are not affected by the dosing regimen; they mainly reflect the important interindividual variability, while remaining fairly stable over time. Many subjects had plasma levels repeatedly outside the assumed therapeutic range. Dose adjustment based on therapeutic drug monitoring may contribute to optimizing antiretroviral therapy.
Publisher Lippincott Williams & Wilkins
ISSN/ISBN 0163-4356
edoc-URL https://edoc.unibas.ch/69549/
Full Text on edoc No
Digital Object Identifier DOI 10.1097/00007691-200108000-00012
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/11477322
ISI-Number WOS:000170128500012
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.328 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
09/05/2024